AUPH at a glance
Aurinia Pharmaceuticals Inc. (AUPH, SEC CIK 1600620) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 19, 2026 and Form 4 insider filings as recently as September 11, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Aurinia Pharmaceuticals Inc. (AUPH) reported revenue of $283.1 million (up 20.4% from FY2024) and net income of $287.2 million. Diluted EPS was $2.07.
- As of June 30, 2026, 28 institutional investment managers tracked by SignalX reported holding Aurinia Pharmaceuticals Inc. (AUPH) shares worth $543.3 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Robertson Stephen P. on September 10, 2026 of 11,939 shares at $15.95 per share.
- In the last 90 days, AUPH insiders reported 0 open-market purchases ($0) and 2 open-market sales ($546K) on Form 4, a net sale of $546K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $283.1M
- +20.4% vs prior year
- Insiders · 90 days
- 0 buys · 2 sells
- Net −$546K
- 13F holders
- 28 funds
- $543.3M · +0 vs prior quarter
- Latest 8-K
- Aug 19, 2026
- Item 8.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: Development and commercialization of LUPKYNIS, an immunosuppressant drug, plus pipeline advancement of aritinercept
- Emphasis on aritinercept clinical development with noted risks of delays, effectiveness, and regulatory approval uncertainty
- Strategic focus this year on patent litigation defense against generic competition, involving paragraph IV ANDA notices and infringement lawsuits
- Notable quantitative metric: U.S. patents for LUPKYNIS extended through December 2037; ongoing significant patent litigation costs expected
- Most noteworthy fact: Increased risk exposure due to patent law changes under Leahy-Smith America Invents Act affecting patent protection and litigation dynamics
Risk Factors
- Regulatory risk: Failure to comply with Medicaid Drug Rebate Program reporting may trigger CMS penalties, FCA allegations, and potential termination risking U.S. reimbursement for LUPKYNIS
- Geopolitical risk: Reliance on Otsuka for commercialization and supply in the Otsuka Territories; failure by either party may limit LUPKYNIS sales in these ex-U.S. markets
- Operational risk: Dependence on Lonza contract manufacturing for LUPKYNIS supply, with shared facility capacity posing production and delivery vulnerabilities
- Competitive risk: LUPKYNIS faces competition from BENLYSTA, GAZYVA, and off-label regimens including tacrolimus, limiting growth potential amid entrenched treatment practices
- Financial risk: High commercial expenditures to maintain sales/marketing capabilities for LUPKYNIS sales growth increase cost structure and business risk
Management Discussion & Analysis
- Revenue $283.1M, up 20% YoY; Net product sales $271.3M up 25%, License revenue $11.7M down 38%
- Gross margin stable at 88%; Operating expenses $178.1M down 26% from $239.8M; Operating income $104.9M vs loss $4.7M
- Best segment: Net product sales $271.3M up $55.2M; worst: License, collaboration $11.7M down $7.2M
- Cash $398.0M, up $39.5M; Operating cash flow $135.7M vs $44.4M; Share repurchases $98.2M, no dividend disclosed
- 2026 SG&A expected flat at ~$101.8M; R&D to increase; Risks from market penetration and raising capital if needed
AI summary of the AUPH 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Quarterly revenue $83.2M, up 19% YoY from $70.0M
- Gross margin 92% vs 90% YoY
- LUPKYNIS net product sales $79.4M, up 19% YoY from $66.6M
- Operating income $46.3M vs $20.1M YoY; net income $37.4M vs $21.5M
- Cash and investments $443.1M vs $398.0M; operating cash flow $85.1M, up 87% YoY; $74.9M share repurchases
- 2026 SG&A expected substantially consistent with 2025; R&D expense expected to increase with development activities
Risk Factors
- No risk-factors section provided; supplied text covers share repurchases and exhibits
- Share repurchase authorization increased by $150 million in July 2025
- Repurchases totaled 23.3 million shares for $213.4 million
- Remaining repurchase capacity $86.634 million as of June 30, 2026
AI summary of the AUPH 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item EX-99.1: Item EX-99.1
- Teva patent settlement removes litigation uncertainty over generic 7.9 mg voclosporin capsules
- Teva acknowledged Aurinia patents valid, enforceable, and infringed by U.S. commercial sales
Item 8.01: Other Events
- Settlement resolves Teva patent litigation over generic 7.9 mg voclosporin capsules in the United States
- Generic-entry timing and launch restrictions depend on settlement terms in Exhibit 99.1
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results for the three months ended June 30, 2026
- Press release issued August 6, 2026, with financial details in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q2 revenue $83.2M, up 19%; LUPKYNIS sales $79.4M, confirming continued commercial momentum
- Six-month net income $71.8M, up 60%; diluted EPS $0.53 versus $0.32
Item 5.07: Submission of Matters to a Vote of Security Holders
- Shareholders re-elected five directors through 2027, with support ranging from 86.50% to 96.59%
- Craig Johnson and Tina S. Nova received comparatively weaker support, at 86.50% and 86.89%
AI summaries of AUPH 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for AUPH
Don't miss the next AUPH filing
- Alerts as it files. A push when AUPH files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut AUPH, by share count.
- Ask anything. An AI agent that reads every AUPH filing and answers with sources.
AUPH alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Robertson Stephen P. | Sell | Sep 10, 2026 | 11,939 | $15.95 |
| Robertson Stephen P. | Sell | Aug 21, 2026 | 20,975 | $16.97 |
| Bailey Jeffrey Allen | A | Jun 4, 2026 | 23,931 | - |
| Nova Tina Susan | A | Jun 4, 2026 | 23,931 | - |
| Goetz Kathleen | A | Jun 4, 2026 | 23,931 | - |
| Johnson Craig A | A | Jun 4, 2026 | 23,931 | - |
| Hearne Michael S | A | May 18, 2026 | 70,230 | - |
| Hearne Michael S | A | May 18, 2026 | 116,144 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $175.5M | $235.1M | $283.1M |
| Operating Income | -$91.7M | -$4.7M | $104.9M |
| Net Income | -$78.0M | $5.8M | $287.2M |
| Op. Margin | -52.2% | -2.0% | 37.1% |
| Net Margin | -44.5% | 2.4% | 101.5% |
| Balance Sheet | |||
| Total Assets | - | $550.6M | $751.6M |
| Equity | $378.0M | $377.5M | $581.3M |
| ROE | -20.6% | 1.5% | 49.4% |
| Per Share | |||
| EPS | $-0.54 | $0.04 | $2.07 |
| Cash Flow | |||
| Operating CF | -$33.5M | $44.4M | $135.7M |
Source: XBRL data in Aurinia Pharmaceuticals Inc. (AUPH)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate AUPH share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 28 | $543.3M |
| Q1 2026 | 28 | $403.2M |
| Q4 2025 | 27 | $409.6M |
| Q3 2025 | 28 | $260.1M |
| Q2 2025 | 28 | $177.7M |
| Q1 2025 | 25 | $115.9M |
| Q4 2024 | 19 | $81.0M |
| Q3 2024 | 16 | $54.0M |
- Goldman Sachs Group+4.19M (+292%)
- BlackRock+347.6K (+4%)
- Wells Fargo & Co+136.7K (+50%)
- Millennium Management+127.1K (+109%)
- Vanguard Portfolio Management LLC+102.7K (+8%)
- D.E. Shaw & Co−164.5K (-10%)
- Bank of America Corp−146.7K (-39%)
- Renaissance Technologies LLC−115.8K (-7%)
- Citadel Advisors LLC−33.9K (-12%)
- Ameriprise Financial−33.4K (-75%)
- Blackstone Group+15.9K
- Marex Group plc−50.0K
Source: 13F-HR filings on SEC EDGAR (aggregated from 199 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
AUPH filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 11, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 8-K | Aug 19, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 8-K | Jun 4, 2026 | - | Analysis | |
| 4 | May 20, 2026 | - | - | |
| 4 | May 20, 2026 | - | - | |
| 4 | May 20, 2026 | - | - | |
| 8-K | May 11, 2026 | - | Analysis | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 7, 2026 | - | Analysis | |
| 8-K | Apr 3, 2026 | - | Analysis | - |
| 8-K | Mar 23, 2026 | - | - | - |
| 4 | Mar 10, 2026 | - | - | - |
| 4 | Mar 3, 2026 | - | - | - |
| 4 | Mar 3, 2026 | - | - | - |
| 4 | Mar 3, 2026 | - | - | - |
| 10-K | Feb 26, 2026 | Dec 31, 2025 | Analysis | |
| 8-K | Feb 26, 2026 | - | - | - |
| 4 | Feb 3, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
AUPH SEC filings: frequently asked questions
Are AUPH insiders buying or selling?
In the last 90 days, Aurinia Pharmaceuticals Inc. (AUPH) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $546,373 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold AUPH stock?
As of June 30, 2026, the largest Aurinia Pharmaceuticals Inc. (AUPH) holders among the 13F filers tracked by SignalX were BlackRock ($139.0 million), Goldman Sachs Group ($95.4 million), Two Sigma Investments ($58.8 million), State Street Corp ($43.9 million), Morgan Stanley ($39.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was AUPH's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Aurinia Pharmaceuticals Inc. (AUPH) reported revenue of $283.1 million (up 20.4% from FY2024) and net income of $287.2 million. Diluted EPS was $2.07. The figures come from the XBRL data in the 10-K.
What are the main risks in AUPH's latest 10-K?
In the 10-K filed February 26, 2026, Aurinia Pharmaceuticals Inc. (AUPH) flagged: Regulatory risk: Failure to comply with Medicaid Drug Rebate Program reporting may trigger CMS penalties, FCA allegations, and potential termination risking U.S. reimbursement for LUPKYNIS. Geopolitical risk: Reliance on Otsuka for commercialization and supply in the Otsuka Territories; failure by either party may limit LUPKYNIS sales in these ex-U.S. markets. (AI summary of the Risk Factors section.)
What did AUPH report in its latest 8-K?
Aurinia Pharmaceuticals Inc. (AUPH) filed an 8-K on August 19, 2026 reporting Item 8.01 (Other Events). Teva patent settlement removes litigation uncertainty over generic 7.9 mg voclosporin capsules.
What are the latest AUPH SEC filings?
Aurinia Pharmaceuticals Inc. (AUPH) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 19, 2026 and a Form 4 insider filing on September 11, 2026.
What is AUPH's SEC CIK number?
Aurinia Pharmaceuticals Inc. (AUPH)'s SEC Central Index Key (CIK) is 1600620. EDGAR lists every AUPH filing under that number.
Ask anything about AUPH
The research agent reads AUPH's filings, financials, insider trades and 13F holders, then answers with sources.